{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:33:08Z","timestamp":1792153988833,"version":"4.4.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000226","name":"Ontario Ministry of Health and Long-Term Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012665","name":"Institute for Clinical Evaluative Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016040","name":"Takeda Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016040","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.clml.2021.05.002","type":"journal-article","created":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T10:30:16Z","timestamp":1620556216000},"page":"e714-e721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Trajectory of Symptoms in Patients Undergoing Autologous Stem Cell Transplant for Multiple Myeloma: A Population-Based Cohort Study of Patient-Reported Outcomes"],"prefix":"10.1016","volume":"21","author":[{"given":"Mohammed S.","family":"Ebraheem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsien","family":"Seow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaris K.","family":"Balitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory R.","family":"Pond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya M.","family":"Wildes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branavan","family":"Sivapathasundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Sussman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.05.002_bib0001","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th Edition","year":"2017"},{"key":"10.1016\/j.clml.2021.05.002_bib0002","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.002_bib0003","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-010713-141500","article-title":"New frontiers in patient-reported outcomes: adverse event reporting, comparative effectiveness, and quality assessment","volume":"65","author":"Basch","year":"2014","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.clml.2021.05.002_bib0004","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/j.bbmt.2018.11.025","article-title":"Patient-reported outcomes with chimeric antigen receptor T cell therapy: challenges and opportunities","volume":"25","author":"Chakraborty","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.05.002_bib0005","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/bmt.2011.130","article-title":"Predictors of health-related quality of life in patients treated with auto- and allo-SCT for hematological malignancies","volume":"47","author":"Braamse","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.05.002_bib0006","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.bbmt.2010.05.017","article-title":"Factors associated with self-reported physical and mental health after hematopoietic cell transplantation","volume":"16","author":"Wingard","year":"2010","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.clml.2021.05.002_bib0007","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.bbmt.2012.11.014","article-title":"Feasibility of frequent patient-reported outcome surveillance in patients undergoing hematopoietic cell transplantation","volume":"19","author":"Wood","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.05.002_bib0008","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1002\/cncr.30936","article-title":"Centralized patient-reported outcome data collection in transplantation is feasible and clinically meaningful","volume":"123","author":"Shaw","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.05.002_bib0009","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/cncr.29717","article-title":"Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902)","volume":"122","author":"Wood","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.05.002_bib0010","first-page":"833","article-title":"Symptom experience of multiple myeloma (syMMex) patients treated with autologous stem cell transplantation following high-dose melphalan: a descriptive longitudinal study","volume":"26","author":"Naegele","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2021.05.002_bib0011","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bbmt.2015.07.036","article-title":"Higher stem cell dose infusion after intensive chemotherapy does not improve symptom burden in older patients with multiple myeloma and amyloidosis","volume":"22","author":"Shah","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.05.002_bib0012","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bbmt.2008.09.023","article-title":"Changes in quality-of-life and psychosocial adjustment among multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation","volume":"15","author":"Sherman","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.05.002_bib0013","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/bmt.2010.304","article-title":"A prospective evaluation of patients\u2019 health-related quality of life during auto-SCT: a 3-year follow-up","volume":"46","author":"Frodin","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.05.002_bib0014","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.bbmt.2017.09.021","article-title":"A comparative assessment of quality of life in patients with multiple myeloma undergoing autologous stem cell transplantation through an outpatient and inpatient model","volume":"24","author":"Martino","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.05.002_bib0015","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3109\/10428194.2014.956313","article-title":"Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma","volume":"56","author":"Wang","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.clml.2021.05.002_bib0016","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1002\/cncr.23299","article-title":"Symptom burden after autologous stem cell transplantation for multiple myeloma","volume":"112","author":"Campagnaro","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.05.002_bib0017","first-page":"350","article-title":"Health-related quality of life in multiple myeloma survivors treated with high dose chemotherapy followed by autologous peripheral blood progenitor cell transplantation: a retrospective analysis","volume":"55","author":"Slovacek","year":"2008","journal-title":"Neoplasma"},{"key":"10.1016\/j.clml.2021.05.002_bib0018","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpainsymman.2012.11.003","article-title":"Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life","volume":"46","author":"Boland","year":"2013","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clml.2021.05.002_bib0019","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/sj.bmt.1705664","article-title":"Symptom burden in patients undergoing autologous stem-cell transplantation","volume":"39","author":"Anderson","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.05.002_bib0020","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.05.002_bib0021","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jpainsymman.2008.12.006","article-title":"Development, implementation, and process evaluation of a regional palliative care quality improvement project","volume":"38","author":"Dudgeon","year":"2009","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clml.2021.05.002_bib0022","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/082585979100700202","article-title":"The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients","volume":"7","author":"Bruera","year":"1991","journal-title":"J Palliat Care"},{"key":"10.1016\/j.clml.2021.05.002_bib0023","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/(SICI)1097-0142(20000501)88:9<2164::AID-CNCR24>3.0.CO;2-5","article-title":"Validation of the Edmonton Symptom Assessment Scale","volume":"88","author":"Chang","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.05.002_bib0024","first-page":"111","article-title":"The Edmonton Symptom Assessment System: a 15-year retrospective review of validation studies (1991-2006)","volume":"22","author":"Nekolaichuk","year":"2008"},{"key":"10.1016\/j.clml.2021.05.002_bib0025","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jpainsymman.2009.06.010","article-title":"A single set of numerical cutpoints to define moderate and severe symptoms for the Edmonton Symptom Assessment System","volume":"39","author":"Selby","year":"2010","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"10.1016\/j.clml.2021.05.002_bib0026","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1681\/ASN.2017080882","article-title":"Causes of death after a hospitalization with AKI","volume":"29","author":"Silver","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clml.2021.05.002_bib0027","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.jpainsymman.2012.06.007","article-title":"Cut points on 0-10 numeric rating scales for symptoms included in the Edmonton Symptom Assessment Scale in cancer patients: a systematic review","volume":"6","author":"Oldenmenger","year":"2013","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clml.2021.05.002_bib0028","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clml.2021.05.002_bib0029","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1136\/jech.2008.083303","article-title":"Neighbourhood chronic stress and gender inequalities in hypertension among Canadian adults: a multilevel analysis","volume":"64","author":"Matheson","year":"2010","journal-title":"J Epidemiol Community Health"},{"key":"10.1016\/j.clml.2021.05.002_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.17.00089","article-title":"Development of an algorithm to distinguish smoldering versus symptomatic multiple myeloma in claims-based data sets","volume":"1","author":"Fiala","year":"2017","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.clml.2021.05.002_bib0031","unstructured":"Pan-Canadian Oncology Drug Review. Provincial funding summary - bortezomib (Velcade) for multiple myeloma. Available at: https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/pcodr-provfund_velcade-mm.pdf. Accessed: December 3, 2020."},{"key":"10.1016\/j.clml.2021.05.002_bib0032","unstructured":"Pan-Canadian Oncology Drug Review. Provincial funding summary - lenalidomide (Revlimid) for multiple myeloma. Available at: https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/pcodr_provfund_revlimid-mm.pdf. Accessed: December 3, 2020."},{"key":"10.1016\/j.clml.2021.05.002_bib0033","article-title":"The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database [e-pub ahead of print]","author":"Cherniawsky","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.05.002_bib0034","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1136\/bmj.316.7139.1236","article-title":"What's wrong with Bonferroni adjustments","volume":"316","author":"Perneger","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2021.05.002_bib0035","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.bbmt.2018.03.027","article-title":"Health-related quality of life after autologous stem cell transplantation for multiple myeloma","volume":"24","author":"Chakraborty","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.05.002_bib0036","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1080\/10428194.2020.1719091","article-title":"Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma","volume":"61","author":"Roussel","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.05.002_bib0037","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1634\/theoncologist.2017-0592","article-title":"Representation of minorities and elderly patients in multiple myeloma clinical trials","volume":"23","author":"Duma","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2021.05.002_bib0038","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1007\/s00277-018-3446-y","article-title":"Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect\u00ae MM Registry","volume":"97","author":"Abonour","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.05.002_bib0039","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/cam4.2656","article-title":"Connect MM Registry as a national reference for United States multiple myeloma patients","volume":"9","author":"Ailawadhi","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2021.05.002_bib0040","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2017.76.0876","article-title":"Symptom burden in the first year after cancer diagnosis: an analysis of patient-reported outcomes","volume":"36","author":"Bubis","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.002_bib0041","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1200\/JCO.2010.30.7173","article-title":"Trajectory of performance status and symptom scores for patients with cancer during the last six months of life","volume":"36","author":"Seow","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.002_bib0042","doi-asserted-by":"crossref","first-page":"453","DOI":"10.21037\/jgo.2019.02.04","article-title":"Gender differences in health-related quality of life among patients with colorectal cancer","volume":"10","author":"Laghousi","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.clml.2021.05.002_bib0043","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/pon.1627","article-title":"The association of depression and anxiety with health-related quality of life in cancer patients with depression and\/or pain","volume":"19","author":"Brown","year":"2010","journal-title":"Psychooncology"},{"key":"10.1016\/j.clml.2021.05.002_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101929","article-title":"Multiple myeloma: role of autologous transplantation","volume":"82","author":"Ntanasis-Stathopoulos","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clml.2021.05.002_bib0045","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/bjh.16764","article-title":"The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?","volume":"191","author":"Kazandjian","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.05.002_bib0046","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jgo.2020.11.003","article-title":"Physical activity is associated with less comorbidity, better treatment tolerance and improved response in patients with multiple myeloma undergoing stem cell transplantation","volume":"12","author":"M\u00f6ller","year":"2021","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.clml.2021.05.002_bib0047","first-page":"573","article-title":"Symptom distress in advanced cancer patients with anxiety and depression in the palliative care setting","volume":"17","author":"Delgado-Guay","year":"2009","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2021.05.002_bib0048","first-page":"45","article-title":"Identifying patients at risk for, and treatment of major psychiatric complications of cancer","volume":"3","author":"Breitbart","year":"1995","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2021.05.002_bib0049","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.clml.2018.08.019","article-title":"Health-related quality of life of patients with multiple myeloma treated in routine clinical practice in France","volume":"19","author":"Despiegel","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.05.002_bib0050","first-page":"417","article-title":"Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study","volume":"22","author":"Jordan","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2021.05.002_bib0051","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma","volume":"11","author":"Cocks","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2021.05.002_bib0052","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-015-1261-6","article-title":"Improving the assessment of quality of life in the clinical care of myeloma patients: the development and validation of the Myeloma Patient Outcome Scale (MyPOS)","volume":"15","author":"Osborne","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2021.05.002_bib0053","first-page":"2789","article-title":"Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life","volume":"23","author":"Baz","year":"2015","journal-title":"Support Care Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021001786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021001786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:37:02Z","timestamp":1761871022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021001786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S2152265021001786"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.05.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trajectory of Symptoms in Patients Undergoing Autologous Stem Cell Transplant for Multiple Myeloma: A Population-Based Cohort Study of Patient-Reported Outcomes","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}